Bimekizumab is currently approved in the United States for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
In a population-based study, male patients with inflammatory joint disease had more children and were less likely to be childless than healthy comparator individuals.